RenovoRx Regains Nasdaq Compliance

RenovoRx Regains Nasdaq Compliance

BenzingaApr 18 20:35

RenovoRx Regains Compliance With Nasdaq Stockholders' Equity Requirement

Shaun Bagai, Chief Executive Officer of RenovoRx, stated, "Regaining compliance with Nasdaq's listing requirements represents another critical achievement for RenovoRx.

Business WireApr 18 20:30

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers important data to potentially assist in optimization of TAMP therapy.

Business WireApr 16 20:30

RenovoRx Secures $11.1M Through Equity and Warrants Offering

TipRanksApr 15 21:12

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway Into 2026

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.

BusinesswireApr 15 20:00

RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement

Cash position now expected to fund current operating plan into 2026Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and toward

BenzingaApr 8 20:36